We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Interleukin-8 Predicts Outcomes for Pediatric Septic Shock

By LabMedica International staff writers
Posted on 27 Aug 2008
Measurement of an immune system protein, interleukin-8 (IL-8) within 24 hours of a child being admitted to a hospital for septic shock has been shown to predict survival.

IL-8 is secreted into the blood as part of the body's immune system response, the chief defense mechanism against infection-related conditions such as septic shock. More...
Previous research has demonstrated that higher blood levels of IL-8 are associated with more severe cases of pediatric septic shock and a greater chance of death. That work also pointed to the potential value of IL-8 as an early diagnostic marker of systemic bacterial infections.

A new study by the same team reported an IL-8 blood level at or below 220 pg/ml should allow doctors to predict with 95% accuracy which of the children with septic shock can survive through conventional antibiotics and therapies for at least 28 days following admission. In addition, measuring IL-8 levels would make it possible to screen lower risk patients out of interventional clinical trials of experimental therapies.

Because the reagents to measure IL-8 are available and blood samples can readily be obtained from patients, Dr. Wong, professor of pediatrics at the University of Cincinnati College of Medicine (OH, USA), is looking to develop a point-of-care test that can be used to detect the IL-8 biomarker in septic shock patients, especially patients being considered for clinical trials.

The study was reported in the August 1, 2008, issue of the American Journal of Respiratory and Critical Care Medicine.

Related Links:
University of Cincinnati College of Medicine



Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.